KSR1

Kinase suppressor of Ras 1 · Q8IVT5 · KSR1 on Sugi Atlas →

0 patent compounds predicted against KSR1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to KSR1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
NEO100 and High-Grade Meningioma PHASE2RECRUITING
Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas PHASE2COMPLETED
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma PHASE2COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) PHASE2WITHDRAWN
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC PHASE2COMPLETED
BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer PHASE2COMPLETED
Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer PHASE1/PHASE2COMPLETED
New Individualized Therapy Trial for Metastatic Colorectal Cancer PHASE1/PHASE2COMPLETED
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation PHASE1/PHASE2RECRUITING
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma PHASE2COMPLETED
Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases PHASE2UNKNOWN
Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1 PHASE2COMPLETED
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer PHASE1/PHASE2COMPLETED
Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation PHASE1RECRUITING
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) PHASE1COMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial nanRECRUITING
RASopathy Biorepository nanRECRUITING
Characterisation of Gene Variants in the Angiogenic Pathway nanUNKNOWN
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer nanUNKNOWN
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment nanACTIVE_NOT_RECRUITING
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications nanCOMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a KSR1 binder may also engage these)

ProteinNameSimilarity
Q61097 1.000 Q61097 →
KSR2 Kinase suppressor of Ras 2 0.997 landscape →
MAP3K9 Mitogen-activated protein kinase kinase kinase 9 0.996 landscape →
Q3UVC0 0.996 Q3UVC0 →
Q3U1V8 0.992 Q3U1V8 →
O08774 0.992 O08774 →
Q1LYM3 0.992 Q1LYM3 →
Q8CGE9 0.991 Q8CGE9 →
Q8R0S2 0.991 Q8R0S2 →
Q9BQI7 0.990 Q9BQI7 →
Q9D684 0.990 Q9D684 →
A0M8T5 0.990 A0M8T5 →
Q08AE8 0.990 Q08AE8 →
Q60610 0.990 Q60610 →
O60292 0.990 O60292 →
Q6DN90 0.990 Q6DN90 →
Q09YK4 0.990 Q09YK4 →
Q80XS6 0.990 Q80XS6 →
A5D794 0.990 A5D794 →
Q5PRF9 0.990 Q5PRF9 →
Q9VLW2 0.990 Q9VLW2 →
Q76LL6 0.990 Q76LL6 →
Q6P1I6 0.989 Q6P1I6 →
Q9Z136 0.989 Q9Z136 →
Q5RJI5 0.989 Q5RJI5 →
Q2IBA2 0.989 Q2IBA2 →
Q9QY01 0.989 Q9QY01 →
Q5JCS6 0.989 Q5JCS6 →
Q09YM8 0.989 Q09YM8 →
PTPN13 Tyrosine-protein phosphatase non-receptor type 13 0.989 landscape →